Who are Tisotumab Vedotin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tivdak, Eptacog alfa (NovoSeven), Hympavzi, BT524 (Part I), BT595, BT524.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tivdak.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Tisotumab Vedotin — Competitive Intelligence Brief

Tisotumab Vedotin (tivdak) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibody-Drug Conjugate (ADC). Area: Oncology.

marketed Antibody-Drug Conjugate (ADC) Tissue factor Oncology Live · refreshed every 30 min

Target snapshot

Tisotumab Vedotin (tivdak) — SEAGEN.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tisotumab Vedotin TARGET	tivdak	SEAGEN	marketed	Antibody-Drug Conjugate (ADC)	Tissue factor	2021-01-01
Tivdak	tisotumab-vedotin	SEAGEN	marketed	Antibody-drug conjugate	Tissue factor	2021-01-01
Eptacog alfa (NovoSeven)	Eptacog alfa (NovoSeven)	Novo Nordisk A/S	marketed	Recombinant coagulation factor	Tissue factor (TF) / Factor X
Hympavzi	Marstacimab-Hncq	Pfizer Inc.	marketed	Tissue Factor Pathway Inhibitor (TFPI) Antagonist	Tissue Factor Pathway Inhibitor (TFPI) Kunitz domain 2 (K2)
BT524 (Part I)	BT524 (Part I)	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BT595	BT595	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)
BT524	BT524	Biotest	phase 3	Monoclonal antibody (anti-TFPI)	Tissue Factor Pathway Inhibitor (TFPI)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibody-Drug Conjugate (ADC) class)

· 1 drug in this class
SEAGEN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tisotumab Vedotin — Competitive Intelligence Brief. https://druglandscape.com/ci/tivdak. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab